Abstract
AimsTo explore associations between polymorphisms of IGF2-related genes including H19, IGF2, IGF2BP2 and IGF2R and Metabolic syndrome (MetS) susceptibility in the Chinese Han population.Methods66 subjects with MetS and 257 control subjects were collected for inclusion in a case-control study. PCR-RFLP was used to investigate polymorphisms in the H19, IGF2, IGF2BP2 and IGF2R genes. Elisa was used to detect the serum IGF2 concentrations.ResultsFemales carrying the GG and AG genotypes of rs680 (IGF2) exhibited a lower risk of MetS, compared with those harboring AA (adjusted OR = 0.388, p = 0.027), while GG and AG genotypes were associated with lower fasting glucose and HbA1c. In males, the Waist-to-Hip Ratio (WHR) and the level of TG were significantly higher in GG and AG genotypes than in the AA genotype of rs680 in IGF2. Levels of HDL-c were lower in men with GG and AG genotypes compared with those carrying the AA genotype. Serum IGF2 concentrations did not change among different genotypes. Finally, multifactor dimensionality reduction (MDR) analysis identified interactions between four polymorphisms: rs3741279 (H19), rs680 (IGF2), rs1470579 (IGF2BP2) and rs629849 (IGF2R).ConclusionsOur study suggests that IGF2-related genes including H19, IGF2, IGF2BP2 and IGF2R genes may play pivotal roles in the development of MetS.
Highlights
Metabolic syndrome (MetS) is a disorder that encompasses a group of symptoms including central obesity, hypertension, hyperglycemia and dyslipidemia [1]
There were no significant associations for rs3741219, rs217727 in the H19 gene, or for rs629849 in the IGF2R gene and rs1470579 in the IGF2BP2 gene for either sex
There was a significant association between the rs680 single nucleotide polymorphisms (SNP) of the IGF2 gene and the risk of MetS in females, though not in males (Supplementary Table 3)
Summary
Metabolic syndrome (MetS) is a disorder that encompasses a group of symptoms including central obesity, hypertension, hyperglycemia and dyslipidemia [1]. The incidence of MetS has increased widely in recent years and always parallels the incidence of obesity and type 2 diabetes (T2DM). According to the International Diabetic Federation (IDF) diabetes atlas, the prevalence of global diabetes was 8.8% in 2015 and is predicted to increase to 10.4% by 2040. Though it’s difficult to measure the global incidence of MetS, it is estimated that around one quarter of the world population has MetS, since MetS is about three times more common than diabetes [2]. Multiple genetic studies have identified numerous mutations that are related to MetS; in particular, genome-wide association studies (GWASs) have maximally revealed MetS-related genetic variants [4,5,6]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
